黑色素瘤辅助治疗新药:医生应继续关注转移性疾病还是更早用于原发性黑色素瘤?
本文区分「晚期辅助治疗」与「早期辅助治疗」两个概念:早期辅助治疗指原发黑色素瘤切除后为清除可能存在的不可检测微小残留病灶而进行的医疗干预,晚期辅助治疗指显性转移性疾病(淋巴结或内脏)完全切除后为优于后续多发转移时再治疗而进行的治疗。作者讨论Ⅱ期黑色素瘤患者短期早期辅助治疗的潜在获益,并希望前哨淋巴结活检与美国癌症联合委员会分期不久能被更相关的生物标志物取代,以识别最适合早期辅助治疗的患者。
要点
- 早期辅助治疗是原发黑色素瘤切除后的预防性策略,晚期辅助治疗旨在提前治疗转移性疾病。
- 靶向治疗与免疫治疗的1年疗程仅在晚期辅助治疗中评估,其结果大致重现了转移性疾病中的显著效应。
- 作者讨论Ⅱ期黑色素瘤短期早期辅助治疗的潜在获益,并希望生物标志物取代前哨淋巴结活检与美国癌症联合委员会分期。
核心结论
- 作者讨论Ⅱ期黑色素瘤患者短期早期辅助治疗的潜在获益,并希望前哨淋巴结活检与美国癌症联合委员会分期不久能被更相关的生物标志物取代,以识别最适合早期辅助治疗的患者。
研究设计与样本
- 本文为Personal View(个人观点)文章,未报告系统检索范围或样本量。
主要发现
- 早期辅助治疗定义为原发黑色素瘤切除后为清除可能存在的不可检测微小残留病灶而进行的医疗干预,属预防性治疗策略。
- 晚期辅助治疗定义为显性转移性疾病(淋巴结或内脏)完全切除后为优于后续多发转移时再治疗而进行的治疗,旨在提前治疗转移性疾病。
- 黑色素瘤患者中,靶向治疗与免疫治疗的1年疗程仅在晚期辅助治疗中评估,其结果大致重现了转移性疾病中的显著效应。
- 早期辅助治疗可能在公共卫生层面提供更大获益,因为无淋巴结转移的薄黑色素瘤非常常见,占黑色素瘤死亡的大多数。
- 在早期辅助治疗中,不足1年的疗程可能足以控制疾病,且毒性更小、成本更低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is important to differentiate between two concepts of adjuvant therapy in melanoma-what we have come to call late adjuvant and early adjuvant therapy. Early adjuvant therapy is defined as a medical intervention that is done after resection of a primary melanoma to eradicate possible undetectable minimal residual disease, whereas late adjuvant therapy is done when an overt metastatic disease (nodal or visceral) has been completely resected, to control disease better than if the same treatment were given at a later time, in the presence of multiple metastases. Early adjuvant therapy is thus a preventive treatment strategy, whereas late adjuvant therapy aims at anticipating treatment of metastatic disease. For patients with melanoma, 1-year treatment with targeted therapies and immunotherapy have only been assessed in late adjuvant settings, the outcomes of which more or less reproduce the same dramatic effect as they have in metastatic disease. However, early adjuvant therapy could provide greater benefits in terms of public health, since thin melanomas without nodal metastases are so common that they account for most deaths by melanoma. In the early adjuvant setting, a treatment course of less than 1 year might be sufficient to control the disease, with less toxicity and at reduced costs. In this Personal View, we discuss the potential benefit of short-term early adjuvant treatment in patients with stage II melanoma, with the hope that sentinel-node biopsy and the American Joint Committee on Cancer staging will soon be replaced by more relevant biomarkers to identify the most suitable candidates for early adjuvant therapy for this disease.
引用
- Grob JJ, Garbe C, Ascierto P, et al. Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? Lancet Oncol. 2018. PMID: 30507438. doi:10.1016/S1470-2045(18)30596-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。